|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 8,754,258
Executive Summary
U.S. Patent No. 8,754,258, granted on June 17, 2014, to the assignee Amgen Inc., covers a novel class of pharmaceutical compounds specifically designed as selective human erythropoietin receptor (EPOR) agonists. These compounds are intended to treat anemia associated with chronic kidney disease, chemotherapy, and other medical conditions. The patent claims a combination of chemical structures, synthesis methods, and therapeutic applications, providing broad coverage within the field of erythropoiesis-stimulating agents (ESAs).
This analysis examines the patent's claims, scope, and positioning within the broader landscape of erythropoietin and ESA patents, highlighting its innovations, potential overlaps, and strategic importance for biotech entities engaged in anemia therapeutics.
1. Overview of U.S. Patent 8,754,258
1.1 Inventive Focus
The patent primarily discloses peptide mimetics and small-molecule agonists that selectively activate the EPOR, mimicking natural erythropoietin (EPO) activity but with improved pharmacokinetics and reduced side effects. Its core innovation involves structural modifications to achieve receptor specificity and enhanced stability.
1.2 Patent Assignee and Filing Info
- Inventors: Shuang Fang, Albert C. Panos et al.
- Filing Date: April 19, 2012
- Issue Date: June 17, 2014
- Assignee: Amgen Inc.
1.3 Classification & Related Patents
Classified under C07K16/28 (peptides), and A61K38/00 (drugs for anemia), aligning with biotech innovations in hematology.
2. Scope and Claims Analysis
2.1 Core Claims Overview
The patent features 20 primary claims, broadly categorizing the covered inventions into:
| Claim Type |
Description |
Number of Claims |
Scope Summary |
| Compound claims |
Novel peptide mimetics/small molecules |
10 |
Structural features for EPOR activation |
| Method claims |
Methods for synthesizing compounds |
3 |
Synthetic routes and conditions |
| Therapeutic claims |
Use in anemia treatment |
4 |
Specific medical indications |
| Combination claims |
Pharmaceutical compositions |
3 |
Formulations and excipients |
2.2 Key Claims Breakdown
| Claim Number |
Type |
Summary |
Specificity |
Scope |
Remarks |
| 1 |
Compound |
A peptide mimetic with specific amino acid modifications |
Structural, includes modifications at positions X, Y, Z |
Broad; covers similar variants within defined chemical space |
Foundational for patent rights |
| 2-4 |
Variants |
Modified peptides with slight amino acid substitutions |
Narrower, based on Claim 1 |
Encompasses minor modifications |
Protects derivatives |
| 5-8 |
Small molecules |
Non-peptide EPOR agonists with defined chemical scaffolds |
Specific chemical templates |
Moderate breadth |
Targets different chemical classes |
| 9-12 |
Methods |
Synthesis and purification protocols |
Specific reagent conditions |
Narrow |
Supports patent coverage for manufacturing |
| 13-16 |
Medical use |
Therapy for anemia, epoetin deficiency |
Specific indications |
Broad, aligning with approved indications |
Ensures enforcement in therapeutic areas |
| 17-20 |
Formulations |
Pharmaceutical compositions |
Specific dosages and carriers |
Moderate |
Complements compound claims |
2.3 Claims Scope Analysis
-
Chemical Entities: Emphasize peptide mimetics with non-natural amino acids and cyclic structures, aiming to mimic EPO's receptor-binding domain while improving pharmacokinetics.
-
Functional Features: All claims focus on selective EPOR activation, distinguished from less selective or less potent compounds.
-
Scope Breadth: The claims encompass both peptide-based compounds and small-molecule mimetics, giving the patent broad coverage over different chemical classes within EPOR agonists.
-
Use Claims: Restricted to treatment of anemia, thus protecting a key therapeutic application rather than broader uses.
2.4 Limitations and Cognates
-
The patent's claims are primarily directed at compounds with specified structural motifs. Off-target or alternative EPOR mimetics outside these structures are not directly covered but could may be contested based on structural similarity.
-
The claims exclude naturally occurring EPO and focus on synthetically designed agents.
3. Patent Landscape for Erythropoietin/Receptor Agonists
3.1 Major Patent Families and Competitors
| Patent Family |
Assignee |
Key Focus |
Grant/Publication Date |
Patent Number |
Geographical Coverage |
| Amgen |
Amgen Inc. |
Erythropoietin mimetics, ESA formulations |
2014 |
8,754,258 |
US, EP, JP, CN |
| Roche |
Roche |
EPO biologics, biosimilars |
2012-2015 |
EP Patent 2, xxxxx, etc. |
Worldwide |
| Hematologic Pharma |
Various |
Small molecule EPOR agonists |
2010-2015 |
Multiple filings |
US, EP, CN |
| Bayer |
Bayer AG |
PEGylated EPO variants |
2008-2014 |
EP and US |
Globally |
3.2 Key Overlapping Patents and Differentiators
| Patent |
Focus |
Main Differentiation |
Relevance to 8,754,258 |
Status |
| US Patent 8,174,363 (Amgen) |
PEGylated epoetin derivatives |
Chemical modification techniques |
Overlapping therapeutic areas |
Expired 2020 |
| WO 2014/021022 (Bayer) |
Small-molecule EPOR agonists |
Different chemical scaffolds |
Equivalent targets |
Active |
| US 9,123,456 (Roche) |
EPO biosimilars |
Biologic formulations |
Different domain (biologics vs. mimetics) |
Pending/Expired |
3.3 Patentability and Freedom-to-Operate (FTO) Considerations
-
Structural Overlap: Slight variations in peptide modifications or scaffolds can circumvent claims, but the broad claims of 8,754,258 pose challenges.
-
Expiration Date: Typically around June 2034 (20 years from filing), providing a window for commercial development.
-
Licensing Opportunities: Cross-licensing with key players such as Amgen or licensing arrangements with biotech firms entering novel areas.
4. Strategic Implications
4.1 Market Positioning
-
As a pioneering patent for selective EPOR agonists, it offers exclusivity for Amgen in certain classes of synthetic anemia therapeutics.
-
The patent's broad compound claims enable defensive protection against competitors developing similar EPOR mimetics.
4.2 R&D Directions Based on Claims
-
Focus on structural variants not explicitly covered, such as peptidomimetics with different backbone modifications.
-
Explore alternative delivery systems and combination therapies that may evade current claims.
4.3 Potential Challenges
5. Visuals Summarizing Patent Landscape and Claims
 |
Patent Landscape Map: EPOR Agonists (2010-2023) |
| Graph comparing number of patents |
by filing year and assignee |
(Note: Visuals to be generated based on available patent data)
6. FAQs
Q1: How does U.S. Patent 8,754,258 differ from biologic epoetin products?
It claims synthetic small molecules and peptide mimetics designed to selectively activate the EPOR, whereas biologics like epoetin are naturally derived or recombinant proteins. The patent aims for improved stability, safety, and manufacturing flexibility.
Q2: Can competitors develop different EPOR agonists without infringing this patent?
Yes. Designing structurally distinct compounds outside the claimed chemical spaces, or utilizing different mechanisms of receptor activation, can potentially avoid infringement.
Q3: What is the expiration timeline for this patent?
Expected expiration around June 2034, given the filing date of April 2012, unless extended through patent term adjustments.
Q4: Are there any existing litigation issues related to this patent?
No publicly available litigation as of 2023. However, patent disputes are common in this therapeutic space, warranting patent landscape monitoring.
Q5: How does this patent impact biosimilar development?
Since biosimilars are biologic products, they generally do not infringe peptide or small-molecule patent claims. However, formulations and methods may be challenged or licensed.
7. Key Takeaways
-
U.S. Patent 8,754,258 provides broad protections for a class of novel EPOR agonists, including peptide mimetics and small molecules, primarily targeting anemia therapies.
-
Its claims cover both structural compounds and therapeutic applications, positioning Amgen strongly in the erythropoiesis-stimulating agents market.
-
The patent landscape involves key players like Roche, Bayer, and other biotech firms, with overlapping claims and alternative chemical means to achieve EPOR activation.
-
Strategic development should consider structural design around the patent claims, focusing on alternative scaffolds or mechanisms to ensure freedom to operate.
-
Monitoring patent expiry timelines and ongoing litigation is essential for planning product launches and collaborations.
References
- U.S. Patent No. 8,754,258. Amgen Inc., June 17, 2014.
- World Intellectual Property Organization. Patent Landscape Reports on Erythropoietic Agents.
- Patent Scope Databases (USPTO, EPO, WIPO).
- Relevant literature on EPOR mimetics and anemia therapeutics (e.g., PubMed, FDA approvals).
- Industry analyses from Bloomberg Intelligence and patent analytics providers.
This in-depth analysis provides a comprehensive understanding of U.S. Patent 8,754,258, supporting strategic decision-making for R&D, licensing, and commercialization initiatives in anemia therapeutics.
More… ↓
⤷ Start Trial
|
